Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 25;19(2):355-364.
doi: 10.5114/aoms/112525. eCollection 2023.

Prognostic value of midkine, syndecan-1, hyaluronan synthase-2, sestrin-1, laminin subunit alpha-4 and fibulin-3 for malignant pleural mesothelioma

Affiliations

Prognostic value of midkine, syndecan-1, hyaluronan synthase-2, sestrin-1, laminin subunit alpha-4 and fibulin-3 for malignant pleural mesothelioma

Hakan Akgun et al. Arch Med Sci. .

Abstract

Introduction: The prognosis of malignant pleural mesothelioma (MPM) is poor, with a limited survival time. In this study, we aimed to examine expression levels of genes selected from relevant literature and to utilize in silico methods to determine genes whose expression could reflect the prognosis of patients with MPM by ex-vivo validation experiments.

Material and methods: The study group consisted of 54 MPM patients treated with chemotherapy. Expression of 6 genes - midkine (MDK), syndecan-1 (SDC1), hyaluronan synthase-2 (HAS2), sestrin-1 (SESN1), laminin subunit alpha-4 (LAMA4), and fibulin-3 (FBLN3) - was examined by qPCR in tumor tissues. Sestrin-1 and LAMA4 were identified using an in house R-based script: Unsupervised Survival Analysis Tool. Midkine, SDC1, HAS2, and FBLN3 were selected from current literature. We used two housekeeping genes, i.e. glucose-6-phosphate dehydrogenase and TATA-box binding protein, as controls.

Results: Of the patients, 43 (79.6%) had epithelioid mesothelioma. The median survival for all patients was 10 (±1.2 SE) months (95% CI: 7.7-12.3). In multivariate analyses, MDK (p = 0.007), HAS2 (p = 0.008) and SESN1 (p = 0.014) expression levels were related to survival time in the whole group. In epithelioid type MPM patients, MDK (p = 0.014), FBLN3 (p = 0.029), HAS2 (p = 0.014) and SESN1 (p = 0.045) expression was related to survival time in multivariate analyses.

Conclusions: High HAS2 and SESN1 expressions and low MDK are potential biomarkers of good prognosis in MPM. High HAS2 and SESN1 expression and low MDK and FBLN3 can also be utilized as biomarkers of good prognosis for epithelioid MPM. Those results should be further investigated in sera, plasma, and pleural effusions.

Keywords: fibulin-3; hyaluronan synthase-2; laminin subunit alpha-4; mesothelioma; midkine; prognosis; sestrin-1; syndecan-1.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Log rank multiple cut-off plots genrated for SESN1 (A), LAMA4 (B), MDK (C), FBLN3 (D), SDC1 (E), HAS2 (F) genes in ex-vivo cohort (n = 54). Horizontal line indicates log rank p value of 0.05. Vertical lines indicates 10th percentile, median and 90th percentile.
Figure 2
Figure 2
Kaplan-Meier survival curves of patients with mesothelioma classified by: A – midkine level in ex-vivo cohort (cutt-off: 2.04); B – syndecan-1 level in ex-vivo cohort (cutt-off: 0.04); C – hayluronan sybthase-2 level in ex-vivo cohort (cutt-off: 0.55); D – sestrin-1 level in ex-vivo cohort (cutt-off: 0.09); E – fibulin 3 level in ex-vivo cohort (cutt-off: 1.04)

Similar articles

Cited by

References

    1. Metintas M, Ozdemir N, Hillerdal G, et al. . Environmental asbestos exposure and malignant pleural mesothelioma. Respir Med 1999; 93: 349-55. - PubMed
    1. Carbone M, Ly BH, Dodson RF, et al. . Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 2012; 227: 44-58. - PMC - PubMed
    1. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995; 108: 1122-8. - PubMed
    1. Metintas M, Metintas S, Ucgun I, et al. . Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. Respir Med 2001; 95: 829-35. - PubMed
    1. Ruffie PA. Pleural mesothelioma. Curr Opin Oncol 1991; 3: 328-34. - PubMed